Advax adjuvant formulations promote protective immunity against aerosol <i>Mycobacterium tuberculosis</i> in the absence of deleterious inflammation and reactogenicity

Abstract The development of safe and effective adjuvants is a critical goal of vaccine development programs. In this report, we defined the immunostimulatory profile and protective effect against aerosol Mycobacterium tuberculosis infection of vaccine formulations incorporating the semi-crystalline adjuvant δ-inulin (Advax). Advax formulated with CpG oligonucleotide and the QS-21 saponin (Advax CpQS ) was the most effective combination, demonstrated by the capacity of CysVac2/Advax CpQS to significantly reduce the bacterial burden in the lungs of M. tuberculosis -infected mice. CysVac2/Advax CpQS protection was associated with rapid influx of neutrophils, macrophages and monocytes to the site of vaccination and the induction of antigen-specific IFN-γ + /IL-2 + /TNF + polyfunctional CD4 + T cells in the lung. When compared to the highly potent adjuvant combination of monophosphoryl lipid A and dimethyldioctadecylammonium bromide (MPL/DDA), Advax CpQS imparted a similar level of protective efficacy yet without the profound stimulation of inflammatory cytokines and vaccination site ulceration observed with MPL/DDA. Addition of DDA to CysVac2/ Advax CpQS further improved the protective effect of the vaccine, which correlated with increased polyfunctional CD4 + T cells in the lung but with no increase in vaccine reactogenicity. The data demonstrate that Advax formulations can decouple protective tuberculosis immunity from reactogenicity, making them ideal candidates for human application. Highlights Advax adjuvant formulations improve pulmonary protection against aerosol Mycobacterium tuberculosis infection Different combinations of adjuvant components markedly influence the level of protection observed Protection is associated with the rapid influx of myeloid cells to the site of vaccination and the induction of antigen-specific polyfunctional CD4 + T cells in the lung. Advax formulations abrogate vaccine-site ulceration and inflammatory cytokine production